Tasly Pharmaceutical Group Co., Ltd.

Market Cap: Large Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: CNE000001C81

CNY

13.87

0.18 (1.31%)

Jun 23

SHG

View all stocks in this country

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Tasly Pharmaceutical Group Co., Ltd.

Why is Tasly Pharmaceutical Group Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of -9.48% and Operating profit at -2.22% over the last 5 years

Negative results in Dec 25

OPERATING CASH FLOW(Y) Lowest at CNY 912.93 MM
NET PROFIT(Q) At CNY 112.86 MM has Fallen at -55.59%
DIVIDEND PAYOUT RATIO(Y) Lowest at 0%

Below par performance in long term as well as near term

Along with generating -5.94% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Tasly Pharmaceutical Group Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Tasly Pharmaceutical Group Co., Ltd. for you?

Low Risk, Low Return

Absolute

Risk Adjusted

Volatility

Tasly Pharmaceutical Group Co., Ltd.

-10.4%

0.15

18.40%

China Shanghai Composite

23.91%

1.58

14.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-6.02%

EBIT Growth (5y)

1.96%

EBIT to Interest (avg)

15.07

Debt to EBITDA (avg)

Net Debt is too low

Net Debt to Equity (avg)

-0.09

Sales to Capital Employed (avg)

0.59

Tax Ratio

16.92%

Dividend Payout Ratio

41.91%

Pledged Shares

Institutional Holding

0.02%

ROCE (avg)

9.92%

ROE (avg)

10.17%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.64

EV to EBIT

14.41

EV to EBITDA

11.46

EV to Capital Employed

1.71

EV to Sales

2.36

PEG Ratio

Dividend Yield

2.22%

ROCE (Latest)

11.90%

ROE (Latest)

7.63%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY 2,297.92 MM

ROCE(HY)

Highest at 9.4%

INTEREST COVERAGE RATIO(Q)

The company hardly has any interest cost

RAW MATERIAL COST(Y)

Fallen by -10.38% (YoY

0What is not working for the Company

NO KEY NEGATIVE TRIGGERS

Here's what is working for Tasly Pharmaceutical Group Co., Ltd.

Operating Cash Flow

Highest at CNY 2,297.92 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Raw Material Cost

Fallen by -10.38% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales